3rd NEW HORIZONS IN IMMUNOTHERAPY FOR HEAD AND NECK CANCER

Friday, June 15, 2018 & Saturday, June 16, 2018

Sponsored by UPMC Center for Continuing Education in the Health Sciences and UPMC Hillman Cancer Center

Renaissance Pittsburgh Hotel
107 6th Street
Pittsburgh, PA 15222

Course Directors
Robert L. Ferris, MD, PhD
R. Bryan Bell, MD, DDS, FACS
Ezra Cohen, MD, FRCPC, FASCO

Intent and Overview
Cancer immunotherapy has rapidly advanced in recent years with two FDA approved agents in the past year. Given the need to disseminate the science and clinical data underlying the clinical benefit observed, and to increase awareness of the role of the immune system in head and neck cancer therapy, as a single modality or in combination with conventional therapies (chemotherapy and radiation), this interactive course has been developed and enhanced from prior meetings and attendee input.

Objectives
1. To provide a forum for leaders in the field of head and neck immuno-oncology to exchange ideas.
2. To provide an opportunity for those with emerging interest in head and neck immuno-oncology to gain an understanding of the currently available immunotherapy agents and a rationale for ongoing and future clinical trials.

Who Should Attend
This conference is designed for leaders in head and neck cancer who are interested in the advancements in the field of immunotherapy for the treatment of cancer patients.

Medical oncologists, radiation oncologists, otolaryngologists, oral surgeons, primary care physicians, pediatricians, family practitioners, nurse practitioners, physician assistants, residents, audiologists, speech therapists, and other interested health care professionals.
Special Needs
Participation by all individuals is encouraged. Advance notification of any special needs will help us provide better service. Please notify us of your needs at least two weeks in advance of the program by e-mailing Mary Kate Ayers at eganmk@upmc.edu.

CME Accreditation and Designation Statement
The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Pittsburgh School of Medicine designates this live activity for a maximum of 14.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other health care professionals are awarded 1.4 continuing education units (CEU’s) which are equal to 14.0 contact hours.

Registration

Registration Fees
- $250 “Early Bird” registration - Early Bird registration is available until April 30, 2018.
- $300 Regular registration - registration on or after May 1, 2018
- Tuition fee is waived for all residents, fellows, international visiting scholars, and medical students, but registration is still required.

Payment is due at time of registration. Payments will be made online with registration at https://ccehs.upmc.com/home.jsf

Cancellations
All cancellations must be in writing and sent to Mary Kate Ayers via e-mail at eganmk@upmc.edu. Tuition for cancellations postmarked or date stamped before June 1, 2018 will be completely refunded. No refunds will be made on or after June 1, 2018. “No shows” are not eligible for refunds.

The UPMC Center for Continuing Education in the Health Sciences reserves the right to cancel this program if sufficient registrations are not received. In the case of cancellation, the department will fully refund registration fees.

Accommodations
A block of rooms are being held at the Renaissance Pittsburgh Hotel. Please contact the hotel to reserve a room by Thursday, May 17, 2018:

Renaissance Pittsburgh Hotel
107 6th Street
Pittsburgh, PA 15222
1-866-915-0479
SCHEDULE
Day 1 of 2: Friday, June 15, 2018

SESSION 1: BIOMARKERS AND ANTI-PD-1/PD-L1

7:30 – 7:55 am  Registration/Breakfast/Exhibits (Visit Exhibitors/Vendors)
7:55 – 8:00 am  Welcome
   Robert L. Ferris, MD, PhD
8:00 – 8:25 am  Current State of Immunotherapy Trials for Head and Neck Cancer
   Ezra Cohen, MD, FRCPC, FASCO
8:25 – 8:35 am  Q&A
8:35 – 9:15 am  Keynote: TCR-Directed Therapies for HPV-Associated Cancer
   Christian S. Hinrichs, MD
9:15 – 9:25 am  Q&A
9:25 – 9:50 am  PD1/PDL1 and Combination Targeting
   Dan P. Zandberg, MD
9:50 – 10:00 am Q&A
10:00 – 10:25 am Next Generation I-O Combinations
   Rom S. Leidner, MD
10:25 – 10:55 am Biomarkers of Response to Successful Anti-PD1 Therapy
   Laura QM Chow, MD, FRCPC
10:55 – 11:10 am Q&A
11:00 – 11:35 am Neoadjuvant Trial Design: Anti-PD1 Prior to Surgery for HNSCC
   Ravindra Uppaluri, MD, PhD, FACS
11:35 – 12:00 pm PD1 Blockade in Cutaneous SCC
   Dan P. Zandberg, MD
12:00 – 12:10 pm Q&A
12:10 – 12:50 pm Lunch/Exhibits (Visit Exhibitors/Vendors)
12:50 – 1:10 pm Developing Neoantigen Selected TIL for HNSCC
   Ezra Cohen, MD, FRCPC, FASCO
Day 1 of 2: Friday, June 15, 2018

**SESSION 2: MODULATING THE TUMOR MICROENVIRONMENT**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:10 – 1:35 pm</td>
<td>The HNSCC Immune Landscape</td>
</tr>
<tr>
<td></td>
<td><em>Luc G. T. Morris, MD, MSc</em></td>
</tr>
<tr>
<td>1:35 – 1:45 pm</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>1:45 – 2:10 pm</td>
<td>New Applications of Multispectral Imaging in Head and Neck Cancer</td>
</tr>
<tr>
<td></td>
<td><em>Bernard A. Fox, PhD</em></td>
</tr>
<tr>
<td>2:10 – 2:35 pm</td>
<td>Targeting iNOS in MDSC</td>
</tr>
<tr>
<td></td>
<td><em>Andrew Sikora, MD, PhD</em></td>
</tr>
<tr>
<td>2:35 – 2:55 pm</td>
<td>STING and Other Inflammatory Agonists in HNSCC Immunotherapy</td>
</tr>
<tr>
<td></td>
<td><em>Young Jun Kim, MD, PhD</em></td>
</tr>
<tr>
<td>2:55 – 3:10 pm</td>
<td>Break/Exhibits (Visit Exhibitors/Vendors)</td>
</tr>
<tr>
<td>3:10 – 3:40 pm</td>
<td><strong>Keynote Lecture:</strong> Mechanism and Application of OX40 Targeting in</td>
</tr>
<tr>
<td></td>
<td>Cancer Patients</td>
</tr>
<tr>
<td></td>
<td><em>Andrew D. Weinberg, PhD</em></td>
</tr>
<tr>
<td>3:40 – 3:55 pm</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>3:55 – 4:20 pm</td>
<td>Targeting Stem Cells and Immunotherapy</td>
</tr>
<tr>
<td></td>
<td><em>John B. Sunwoo, MD</em></td>
</tr>
<tr>
<td>4:20 – 4:45 pm</td>
<td>Altering Macrophage Polarity in HNSCC</td>
</tr>
<tr>
<td></td>
<td><em>Judith A. Varner, PhD</em></td>
</tr>
<tr>
<td>4:45 – 4:55 pm</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>4:55 pm</td>
<td>Adjournment Day 1 of 2</td>
</tr>
<tr>
<td>6:00 pm</td>
<td>Reception – Renaissance Hotel</td>
</tr>
</tbody>
</table>
SESSION 3: STRATEGIES FOR RATIONAL COMBINATIONS

7:30 – 8:00 am  Breakfast/Exhibits (Visit Exhibitors/Vendors)

8:00 – 8:25 am  Surgery as a Platform for Immunotherapy
    R. Bryan Bell, MD, DDS, FACS

8:25 – 8:50 am  Metabolic Changes in the TME Affect Immunotherapy
    Greg M. Delgoffe, PhD

8:50 – 9:15 am  Harnessing Genomics to Enhance Immunotherapy: Building a Neoadjuvant: Neoantigen Platform for Patient Specific Immunotherapy
    Nadeem Riaz, MD, MSc

9:15 – 9:25 am  Q&A

9:25 – 9:50 am  **Keynote**: Treg Stability and Harnessing the TME for Immunotherapy
    Dario Vignali, PhD

9:50 – 10:00 am  Q&A

10:00 – 10:15 am  Break/Exhibits (Visit Exhibitors/Vendors)

10:15 – 10:55 am  Radiation Therapy and PI3K Targeting of Myeloid Cells
    Andrew Sharabi, MD, PhD

10:55 – 11:05 am  Role of Tumor Infiltrating B Cells in Head and Neck Cancer
    Tullia C. Bruno, PhD

11:05 – 11:15 am  Q&A

11:15 – 11:35 am  Intersection of DNA Damage and Immune Escape: Immune and Genomic Checkpoints
    Christopher J. Bakkenist, PhD

11:35 – 12:00 pm  Radiation and Immunotherapy Using DNA Damage Inhibition
    David A. Clump, MD, PhD

12:00 – 12:10 pm  Q&A

12:10 – 1:00 pm  Lunch/Exhibits (Visit Exhibitors/Vendors)
Day 2 of 2: Saturday, June 16, 2018

SESSION 4: NEOANTIGENS AND ADOPTIVE CELL THERAPY

1:00 – 1:25 pm  Immunocompetent HNSCC Mouse Models  
*J. Silvio Gutkind, PhD*

1:25 – 1:50 pm  Chemoimmunotherapy: Risks, Benefits and Alternatives  
*Nicole C. Schmitt, MD*

1:50 – 2:00 pm  Q&A

2:00 – 2:25 pm  Sensitizing HNSCC to immune checkpoint blockade through G2/M cell cycle checkpoint abrogation  
*Clint T. Allen, MD, FACS*

2:25 – 2:50 pm  TILs to TCRs: A Strategy for Developing Adoptive Immunotherapy for Solid Tumors  
*Udai S. Kammula, MD, FACS*

2:50 – 3:00 pm  Q&A

3:00 pm  Adjournment Day 2 of 2

Course Directors

Robert L. Ferris, MD, PhD  
Hillman Professor of Oncology and Director  
UPMC Hillman Cancer Center  
Associate Vice-Chancellor for Cancer Research  
Co-Director, Tumor Microenvironment Center  
Professor of Otolaryngology, of Immunology, and of Radiation Oncology  
University of Pittsburgh School of Medicine  
Pittsburgh, PA

R. Bryan Bell, MD, DDS, FACS  
Medical Director, Providence Oral, Head and Neck Cancer Program and Clinic  
Earle A. Chiles Research Institute in the Robert W. Franz Cancer Center at Providence  
Portland Medical Center  
Portland, OR

Ezra Cohen, MD, FRCPSC, FASCO  
Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, UC San Diego  
Co-director, San Diego Center for Precision Immunotherapy  
Associate Director for Translational Science, Moores Cancer Center  
Co-leader, Solid Tumor Therapeutics Program  
Co-director, Head and Neck Cancer Center of Excellence  
San Diego, CA
Guest Faculty

Clint T. Allen, MD, FACS  
Associate Professor  
Johns Hopkins School of Medicine and The National Institutes of Health  
Bethesda, MD

Laura QM Chow, MD, FRCPC  
Associate Professor  
University of Washington  
Seattle, WA

Bernard A. Fox, PhD  
Harder Family Chair for Cancer Research, Member and Chief, Laboratory of Molecular and Tumor Immunology  
Earle A Chiles Research Institute  
Robert W. Franz Cancer Center  
Providence Portland Medical Center  
Portland, OR

J. Silvio Gutkind, PhD  
Professor, Department of Pharmacology  
Associate Director of Basic Science  
UC San Diego Moores Cancer Center  
La Jolla, CA

Christian S. Hinrichs, MD  
Investigator, Lasker Scholar  
National Cancer Institute  
Bethesda, MD

Young Jun Kim, MD, PhD, FACS  
Amy & Barry Baker Endowed Chair  
Co-Leader, Translational Research & Interventional Oncology  
Director, Head & Neck Oncologic Research, Vanderbilt-Ingram Cancer Center  
Associate Professor, Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center  
Vanderbilt University Medical Center  
Nashville, TN

Rom S. Leidner, MD  
Co-Director, Providence Oral, Head, and Neck Cancer Program  
Assistant Member, Earle A. Chiles Research Institute

Luc G.T. Morris, MD, MSc  
Adlerian Chair and Associate Professor of Surgery  
Associate Director, Immunogenomics and Precision Oncology Platform  
Memorial Sloan Kettering Cancer Center  
New York, NY

Nadeem Riaz, MD, MSc  
Assistant Attending, Department of Radiation Oncology  
Associate Director, Immunogenomics and Precision Oncology Platform  
Memorial Sloan Kettering Cancer Center  
New York, NY

Nicole C. Schmitt, MD  
Assistant Professor, Division of Head and Neck Surgery  
Department of Otolaryngology- Head and Neck Surgery  
Johns Hopkins University  
Baltimore, MD

Andrew Sharabi, MD, PhD  
Assistant Professor  
University of California at San Diego  
Radiation Medicine & Applied Sciences  
San Diego, CA

Andrew Sikora, MD, PhD  
Associate Professor and Caroline Weiss Law Translational Research Scholar  
Department of Otolaryngology, Baylor College of Medicine  
Houston, TX

John B. Sunwoo, MD  
Associate Professor  
Stanford University  
Stanford, CA

Ravindra Uppaluri, MD, PhD, FACS  
Director, Head and Neck Surgical Oncology, Chief, Division of Otolaryngology, Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School
Guest Faculty

Judith A. Varner, PhD
Professor of Pathology and Medicine
Moores Cancer Center
University of California, San Diego
La Jolla, CA

Andrew D. Weinberg, PhD
Judy Ann Hartmann Endowed Chair for Cancer Immunology Research,
Member and Chief, Laboratory of Basic Immunology
Earle A Chiles Research Institute
Robert W. Franz Cancer Center
Providence Portland Medical Center
Portland, OR

Local Faculty

Christopher J. Bakkenist, PhD
Associate Professor of Radiation Oncology
Vice Chair for Basic Science
University of Pittsburgh, School of Medicine
Pittsburgh, PA

Udai S. Kammula, MD, FACS
Director, Solid Tumor Cell Therapy Program
UPMC Hillman Cancer Center
Associate Professor, Division of Surgical Oncology
University of Pittsburgh School of Medicine
Pittsburgh, PA

Tullia Bruno, PhD
Research Assistant Professor
University of Pittsburgh
Pittsburgh, PA

Dario Vignali, PhD
Frank Dixon Chair in Cancer Immunology
Professor & Vice Chair of Immunology
Leader of the Cancer Immunology Program
Co-Director of the Tumor Microenvironment Center
Scientific Director of Fondazione Ri.MED
University of Pittsburgh
Pittsburgh, PA

David A. Clump, MD, PhD
Assistant Professor
Department of Radiation Oncology
UPMC Hillman Cancer Center
Pittsburgh, PA

Greg M. Delgoffe, PhD
Assistant Professor
Tumor Microenvironment Center
Department of Immunology
University of Pittsburgh Cancer Institute
UPMC Hillman Cancer Center
Pittsburgh, PA

Dan P. Zandberg, MD
Associate Professor of Medicine
Director, Head and Neck Cancer and Thyroid Cancer Disease Sections
Division of Hematology/Oncology
UPMC Hillman Cancer Center
Pittsburgh, PA

Faculty Disclosure
All individuals in a position to control the content of this education activity are required to disclose all relevant financial relationships with any proprietary entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.

Visit the Center for Continuing Education in the Health Sciences Web Site
The UPMC/Center for Continuing Education in the Health Sciences invites you to visit our web location. Receive information on CME programs, earn CME credits on the Internet, and access information about our formal courses and much more. Discover who we are and how you can contact us. Please visit our web location often to get updated information on upcoming programs: http://ccehs.upmc.com

The University of Pittsburgh is an affirmative action, equal opportunity institution.